Metals Biology and Molecular Medicine Group, Eunice Kennedy Shriver National Institute of Child Health and Human Development, and.
Veterinary Resources Program, National Institutes of Health, Bethesda, MD.
Blood Adv. 2018 Oct 23;2(20):2732-2743. doi: 10.1182/bloodadvances.2018019737.
Heme oxygenase 1 (HMOX1), the inducible enzyme that catabolizes the degradation of heme into biliverdin, iron, and carbon monoxide, plays an essential role in the clearance of senescent and damaged red blood cells, systemic iron homeostasis, erythropoiesis, vascular hemostasis, and oxidative and inflammatory stress responses. In humans, HMOX1 deficiency causes a rare and lethal disease, characterized by severe anemia, intravascular hemolysis, as well as vascular and tissue damage. knockout (KO) mice recapitulated the phenotypes of HMOX1-deficiency patients and could be rescued by bone marrow (BM) transplantation that engrafted donor's hematopoietic stem cells into the recipient animals after myeloablation. To find better therapy and elucidate the contribution of macrophages to the pathogenesis of HMOX1-deficiency disease, we infused wild-type (WT) macrophages into KO mice. Results showed that WT macrophages engrafted and proliferated in the livers of KO mice, which corrected the microcytic anemia, rescued the intravascular hemolysis, restored iron homeostasis, eliminated kidney iron overload and tissue damage, and provided long-term protection. These results showed that a single macrophage infusion delivered a long-term curative effect in KO mice, obviating the need for BM transplantation, and suggested that the HMOX1 disease stems mainly from the loss of viable reticuloendothelial macrophages. Our work provides new insights into the etiology of HMOX1 deficiency and demonstrates the potential of infusion of WT macrophages to prevent disease in patients with HMOX1 deficiency and potentially other macrophage-related diseases.
血红素加氧酶 1(HMOX1)是一种诱导酶,可分解血红素为胆绿素、铁和一氧化碳,在清除衰老和受损的红细胞、维持全身铁平衡、红细胞生成、血管止血以及氧化和炎症应激反应中发挥重要作用。在人类中,HMOX1 缺乏会导致一种罕见且致命的疾病,其特征为严重贫血、血管内溶血以及血管和组织损伤。HMOX1 基因敲除(KO)小鼠重现了 HMOX1 缺乏症患者的表型,并且可以通过骨髓(BM)移植得到挽救,该方法是在骨髓清除后将供体造血干细胞移植到受体动物中。为了寻找更好的治疗方法并阐明巨噬细胞对 HMOX1 缺乏症发病机制的贡献,我们将野生型(WT)巨噬细胞输注到 KO 小鼠中。结果显示,WT 巨噬细胞在 KO 小鼠的肝脏中植入和增殖,纠正了小细胞性贫血,挽救了血管内溶血,恢复了铁平衡,消除了肾脏铁过载和组织损伤,并提供了长期保护。这些结果表明,单次巨噬细胞输注在 KO 小鼠中产生了长期的治疗效果,无需进行 BM 移植,并且提示 HMOX1 疾病主要源于有活力的网状内皮巨噬细胞的丧失。我们的工作为 HMOX1 缺乏症的病因学提供了新的见解,并证明了输注 WT 巨噬细胞预防 HMOX1 缺乏症患者和潜在的其他与巨噬细胞相关疾病的疾病的潜力。